Gramics Bio

Gramics Bio develops a gene therapy platform solving a key limitation of lipid nanoparticle delivery: enabling therapeutic DNA to reach the cell nucleus for durable expression without viral vectors. By programming specificity into synthetic DNA sequences rather than new delivery chemistries, the technology combines the durability of viral gene therapy with the safety and manufacturability of lipid nanoparticle systems. The company's lead programme targets cystic fibrosis, with planned expansion into other genetic diseases.